Title: Recent advancements in drug treatment of obesity.
Journal: Clinical medicine (London, England)20121001
Title: Two new drugs approved for obesity.
Journal: South Dakota medicine : the journal of the South Dakota State Medical Association20120901
Title: Insurers find small gains in weight control with Belviq.
Journal: Managed care (Langhorne, Pa.)20120801
Title: Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
Journal: Obesity (Silver Spring, Md.)20120701
Title: The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology20120401
Title: Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin.
Journal: Drug metabolism and disposition: the biological fate of chemicals20120401
Title: Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist.
Journal: Drug metabolism and disposition: the biological fate of chemicals20120401
Title: [The pharmacological treatment of obesity: past, present and future].
Journal: Orvosi hetilap20120311
Title: What cost weight loss?
Journal: Circulation20120306
Title: Serotonergic anti-obesity agents: past experience and future prospects.
Journal: Drugs20111203
Title: Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists20111101
Title: Should the FDA approval process for weight-loss drugs be modified?
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists20111101
Title: A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Journal: The Journal of clinical endocrinology and metabolism20111001
Title: Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.
Journal: The Journal of pharmacology and experimental therapeutics20110901
Title: Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.
Journal: Clinical pharmacology and therapeutics20110501
Title: Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
Journal: The Journal of clinical endocrinology and metabolism20110301
Title: Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
Journal: Expert review of cardiovascular therapy20110301
Title: The use of lorcaserin in the management of obesity: a critical appraisal.
Journal: Drug design, development and therapy20110101
Title: Trial of lorcaserin for weight management.
Journal: The New England journal of medicine20101216
Title: Trial of lorcaserin for weight management.
Journal: The New England journal of medicine20101216
Title: Trial of lorcaserin for weight management.
Journal: The New England journal of medicine20101216
Title: Lorcaserin--not a new weapon in the battle with appetite.
Journal: Nature reviews. Endocrinology20101201
Title: Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
Journal: Future medicinal chemistry20101201
Title: Lorcaserin for the treatment of obesity.
Journal: Drugs of today (Barcelona, Spain : 1998)20101201
Title: ACS chemical neuroscience molecule spotlight on Lorcaserin.
Journal: ACS chemical neuroscience20101117
Title: Fat attack.
Journal: Scientific American20100901
Title: Multicenter, placebo-controlled trial of lorcaserin for weight management.
Journal: The New England journal of medicine20100715
Title: Drug management of obesity--efficacy versus safety.
Journal: The New England journal of medicine20100715
Title: Market watch: upcoming market catalysts in Q3 2010.
Journal: Nature reviews. Drug discovery20100701
Title: Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference.
Journal: IDrugs : the investigational drugs journal20100401
Title: Pharmacologic therapies for obesity.
Journal: Gastroenterology clinics of North America20100301
Title: Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
Journal: Expert review of cardiovascular therapy20091101
Title: Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice.
Journal: Neuropharmacology20090901
Title: Medicinal chemistry strategies in follow-on drug discovery.
Journal: Drug discovery today20090501
Title: Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
Journal: Obesity (Silver Spring, Md.)20090301
Title: Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
Journal: Current opinion in drug discovery & development20080701
Title: Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
Journal: The Journal of pharmacology and experimental therapeutics20080501
Title: Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
Journal: Journal of medicinal chemistry20080124
Title: APD-356 (Arena).
Journal: Current opinion in investigational drugs (London, England : 2000)20051001
